Stay up to date on the issues impacting the industry and be the first to hear about news and changes at Rael & Letson.
Drug rebates are meant to lower costs, but limited transparency and misaligned incentives raise questions. Learn how employers can evaluate PBM practices and ensure their plan delivers real value and long-term savings.
Read moreLearn what the Actuarial Standards of Practice have to say about these controversial topics, and what they mean for a client’s retiree health valuation.
Read morePaul Graf will speak on mitigating multiemployer plan risk at the virtual Conference of Consulting Actuaries on May 9.
Read moreWe are excited to welcome Kateryna Pryor, ASA, MAAA, to our Retiree Health team with her expertise working with public agencies on retiree health issues.
Read moreParticipant communication is essential for improving engagement, but how do you know if your outreach is working?
Read moreWe are excited to welcome Martin Fornataro, Pharm.D., to our PBM Consulting team.
Read moreAfter a wave of FDA approvals, annual spending on CGTs is estimated to increase from $5.15 billion in 2020 to $25.3 billion in 2026! What does this mean for your plan?
Read moreParticipant communication is essential for improving engagement, but how do you know if your outreach is working?
Read moreWhy can't an actuary make up any number for a retiree health valuation liability - what's it matter?! Learn why it does matter if the actuary wants to stay an actuary.
Read moreOn January 10, 2025, the IRS issued proposed regulations regarding automatic enrollment and catch-up contribution provisions of the SECURE 2.0 Act of 2022.
Read more